奥希替尼二甲磺酸盐 T10433

Product Introduction
Bioactivity


英文名: Osimertinib dimesylate

描述: Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).

体外活性: Osimertinib (AZD-9291) shows similar potency to early generation tyrosine kinase inhibitor in inhibiting EGFR phosphorylation in EGFR cells harboring sensitizing EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del) (mean IC50s: 13 to 54 nM). Osimertinib also potently inhibits phosphorylation of EGFR in T790M mutant cell lines H1975 (L858R/T790M), PC-9VanR (ex19del/T790M), with mean IC50 potency less than 15 nM [1].

体内活性: The tumor-bearing mice are treated with Osimertinib (5 mg/kg/day) for one to two weeks. Within days of treatment, 5 of 5 C/L858R mice display nearly 80% reduction in tumor volume by magnetic resonance imaging MRI after therapy with Osimertinib, while 5 of 5 mice treated with vehicle shows tumor growth [1]. Upon dosing Osimertinib in three efficacy models, comparable efficacy is observed at relatively low doses (10 mg/kg per day). The excellent efficacy is also observed when Osimertinib is dosed at 5 mg/kg per day [2].

存储条件: keep away from direct sunlightPowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 0.4 mg/mL (0.58 mM)


关键字: Osimertinib Dimesylate | AZD 9291 | Osimertinib | Mereletinib | Osimertinib dimesylate | AZD9291 | AZD-9291

相关产品: AG-494 | EAI001 | Khellin | ALK/EGFR-IN-1 | Cloperastine fendizoate | WZ8040 | Cisapride hydrate | PD173074 | MTX-241F | Mobocertinib

奥希替尼二甲磺酸盐 T10433信息由TargetMol中国为您提供，如您想了解更多关于奥希替尼二甲磺酸盐 T10433报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途